All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Ruxolitinib for treatment of sclerotic cGvHD: Results from a phase II study
By Ella Dixon
|
Sclerotic chronic graft-versus-host (cGvHD) is a highly-refractory form of cGvHD associated with high morbidity.1 The biology of sclerotic cGvHD differs to other forms of cGvHD; however, there is a lack of clinical trials investigating treatments for sclerotic cGvHD. A multicenter phase II trial assessing the efficacy and safety of ruxolitinib in 47 adult patients with sclerotic cGvHD refractory to corticosteroid and other systemic therapies was published in the Journal of Clinical Oncology by Bhatt et al.1 |
| Key learnings: |
|
At 6 months, partial response in skin and/or joints was achieved in 49% of ruxolitinib-treated patients, with 45% showing a response in joints/fascia and 19% in the skin. |
|
The overall partial response rate was 47%, with 77% of patients maintaining skin/joint response at 12 months. The failure-free survival rate at 12 months was 77.1%. |
|
38% of patients showed improvement in the Lee Symptom Scale summary and skin subscale scores, reflecting enhanced symptom management. |
|
Grade ≥3 adverse events occurred in 40% of patients, with 13% of these related to ruxolitinib. At 12 months, the cumulative incidence of non-relapse mortality and treatment failure was 2.2% and 20.8%, respectively. No cases of recurrent malignancy were observed. |
|
These findings suggest that ruxolitinib was associated with high response rates and was well tolerated, offering a promising treatment option for refractory sclerotic cGvHD. Its favorable safety and efficacy profile may support its use in earlier treatment lines and in combination with other emerging therapies. |
- Bhatt VR, Shostrom VK, Choe HK, et al. A multicenter phase II trial of ruxolitinib for treatment of corticosteroid refractory sclerotic chronic graft-versus-host disease. J Clin Oncol. Online ahead of print. DOI: 10.1200/JCO.24.00205
Your opinion matters
4 votes - 57 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox